STERIS plc (NYSE:STE) Stock Holdings Trimmed by Gulf International Bank UK Ltd

Gulf International Bank UK Ltd decreased its position in STERIS plc (NYSE:STE - Free Report) by 61.0% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 7,794 shares of the medical equipment provider's stock after selling 12,207 shares during the quarter. Gulf International Bank UK Ltd's holdings in STERIS were worth $1,890,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in STE. Central Pacific Bank Trust Division purchased a new stake in shares of STERIS during the 3rd quarter worth $28,000. J.Safra Asset Management Corp lifted its holdings in STERIS by 77.9% in the first quarter. J.Safra Asset Management Corp now owns 121 shares of the medical equipment provider's stock worth $27,000 after acquiring an additional 53 shares during the last quarter. Quent Capital LLC lifted its holdings in STERIS by 112.7% in the first quarter. Quent Capital LLC now owns 134 shares of the medical equipment provider's stock worth $30,000 after purchasing an additional 71 shares during the period. Headlands Technologies LLC purchased a new stake in shares of STERIS during the first quarter valued at $36,000. Finally, Versant Capital Management Inc increased its stake in shares of STERIS by 2,262.5% during the 2nd quarter. Versant Capital Management Inc now owns 189 shares of the medical equipment provider's stock worth $41,000 after purchasing an additional 181 shares during the last quarter. 94.69% of the stock is owned by hedge funds and other institutional investors.

STERIS Price Performance

NYSE:STE traded up $3.64 during midday trading on Friday, hitting $219.14. The company had a trading volume of 1,071,783 shares, compared to its average volume of 490,598. The company has a quick ratio of 1.49, a current ratio of 2.33 and a debt-to-equity ratio of 0.35. The company has a market capitalization of $21.61 billion, a PE ratio of 49.20 and a beta of 0.85. The stock's fifty day moving average price is $232.73 and its 200-day moving average price is $227.52. STERIS plc has a 52-week low of $195.47 and a 52-week high of $248.24.

STERIS (NYSE:STE - Get Free Report) last posted its earnings results on Wednesday, November 6th. The medical equipment provider reported $2.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.11 by $0.03. The firm had revenue of $1.33 billion during the quarter, compared to analysts' expectations of $1.33 billion. STERIS had a net margin of 8.02% and a return on equity of 13.91%. The business's revenue was up 7.3% compared to the same quarter last year. During the same period in the previous year, the business posted $2.03 EPS. As a group, research analysts expect that STERIS plc will post 9.02 earnings per share for the current year.

STERIS Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 19th. Stockholders of record on Tuesday, November 19th will be issued a dividend of $0.57 per share. This represents a $2.28 dividend on an annualized basis and a dividend yield of 1.04%. The ex-dividend date is Tuesday, November 19th. STERIS's dividend payout ratio is 52.05%.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on STE. JMP Securities reiterated a "market outperform" rating and issued a $265.00 price objective on shares of STERIS in a research report on Wednesday, August 7th. Stephens reiterated an "overweight" rating and issued a $260.00 price objective on shares of STERIS in a research note on Thursday. KeyCorp raised their price objective on STERIS from $255.00 to $265.00 and gave the company an "overweight" rating in a report on Tuesday, September 3rd. Piper Sandler upgraded shares of STERIS from a "neutral" rating to an "overweight" rating and raised their target price for the stock from $230.00 to $260.00 in a report on Thursday, October 24th. Finally, StockNews.com cut STERIS from a "strong-buy" rating to a "buy" rating in a research note on Tuesday, October 29th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, STERIS currently has an average rating of "Moderate Buy" and an average price target of $253.00.

Insider Transactions at STERIS

In related news, CFO Michael J. Tokich sold 23,332 shares of STERIS stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $247.00, for a total value of $5,763,004.00. Following the completion of the sale, the chief financial officer now owns 42,930 shares of the company's stock, valued at approximately $10,603,710. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 1.14% of the stock is owned by company insiders.

STERIS Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.